Co-Diagnostics Inc
NASDAQ:CODX

Watchlist Manager
Co-Diagnostics Inc Logo
Co-Diagnostics Inc
NASDAQ:CODX
Watchlist
Price: 1.01 USD -4.72% Market Closed
Market Cap: 32.2m USD
Have any thoughts about
Co-Diagnostics Inc?
Write Note

Co-Diagnostics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Co-Diagnostics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Co-Diagnostics Inc
NASDAQ:CODX
Operating Income
-$40m
CAGR 3-Years
N/A
CAGR 5-Years
-46%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Operating Income
$2.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
Operating Income
$2.9B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Operating Income
$4.8B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Operating Income
$6.9B
CAGR 3-Years
-7%
CAGR 5-Years
10%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.1B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Co-Diagnostics Inc
Glance View

Market Cap
32.2m USD
Industry
Health Care

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

CODX Intrinsic Value
0.38 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Co-Diagnostics Inc's Operating Income?
Operating Income
-40m USD

Based on the financial report for Sep 30, 2024, Co-Diagnostics Inc's Operating Income amounts to -40m USD.

What is Co-Diagnostics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-46%

Over the last year, the Operating Income growth was 4%.

Back to Top